Ensysce shareholders approve share issuance to investor and incentive plan increase

Ensysce Biosciences, Inc.

Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.
Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 121,457 to 721,457.
Class I directors William Chang and Lee Rauch reelected; Chang: 518,597 for, Rauch: 516,907 for.
Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2025.

item 5.07

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-000994
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2026-01-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.987885+00:00
generated_at: 2026-05-16T11:13:37.767851+00:00
sec_items: ["5.07"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-000994
json_url: https://secwatch.observer/filing/0001493152-26-000994.json
markdown_url: https://secwatch.observer/filing/0001493152-26-000994.md
text_url: https://secwatch.observer/filing/0001493152-26-000994.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226000994/0001493152-26-000994-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226000994/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-000994

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.